Study of Efficacy and Safety of Ormeloxifene in the Management of Dysfunctional Menorrhagia

Objective: To assess the efficacy and safety of ormeloxifene in the medical management of dysfunctional menorrhagia. Methodology: Fifty women with menorrhagia were recruited for the study. Ormeloxifene 60 mg twice a week for 3 months from first day of periods and once a week for next 3 months was given. Mean blood loss (MBL) was assessed using pictorial blood loss assessment chart (PBAC). Ultrasonography (USG) and blood hemoglobin levels were done as baseline and at 2, 4 and 6 months of treatment. Side-effects of the drug were recorded. Changes in PBAC scoring, endometrial thickness (ET) and hemoglobin levels (Hb) were analyzed by student’s paired ‘t’ tests using SPSS 17.0 version. p value ≤ 0.05 was taken as significant. Results: The pretreatment PBAC score was 360, which reduced to 209.5 at 2 months, 88.7 at 4 months and 68.2 at 6 months of treatment, which was statistically significant (p-value ≤ 0.001). The rise in hemoglobin and decrease in ET, in women on ormeloxifene was also statistically significant (p-value ≤ 0.001). Conclusion: Ormeloxifene is an effective and safe therapeutic option for the medical management of menorrhagia.